- Home
- HOOK vs TRIB Comparison
HOOK vs TRIB Comparison
Compare HOOK & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- TRIB
- Stock Information
- Founded
- HOOK 2011
- TRIB 1992
- Country
- HOOK United States
- TRIB Ireland
- Employees
- HOOK N/A
- TRIB N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HOOK Health Care
- TRIB Health Care
- Exchange
- HOOK Nasdaq
- TRIB Nasdaq
- Market Cap
- HOOK 15.3M
- TRIB 13.0M
- IPO Year
- HOOK 2019
- TRIB N/A
- Fundamental
- Price
- HOOK $1.20
- TRIB $0.78
- Analyst Decision
- HOOK Buy
- TRIB
- Analyst Count
- HOOK 4
- TRIB 0
- Target Price
- HOOK $10.67
- TRIB N/A
- AVG Volume (30 Days)
- HOOK 67.1K
- TRIB 2.4M
- Earning Date
- HOOK 08-07-2025
- TRIB 08-13-2025
- Dividend Yield
- HOOK N/A
- TRIB N/A
- EPS Growth
- HOOK N/A
- TRIB N/A
- EPS
- HOOK N/A
- TRIB N/A
- Revenue
- HOOK $9,351,000.00
- TRIB $61,555,000.00
- Revenue This Year
- HOOK N/A
- TRIB $13.51
- Revenue Next Year
- HOOK N/A
- TRIB $13.14
- P/E Ratio
- HOOK N/A
- TRIB N/A
- Revenue Growth
- HOOK N/A
- TRIB 8.31
- 52 Week Low
- HOOK $0.72
- TRIB $0.48
- 52 Week High
- HOOK $6.77
- TRIB $3.44
- Technical
- Relative Strength Index (RSI)
- HOOK 39.18
- TRIB 56.63
- Support Level
- HOOK $1.13
- TRIB $0.70
- Resistance Level
- HOOK $1.35
- TRIB $0.77
- Average True Range (ATR)
- HOOK 0.06
- TRIB 0.08
- MACD
- HOOK -0.01
- TRIB 0.01
- Stochastic Oscillator
- HOOK 40.64
- TRIB 60.45
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.